Esther Nérida Sánchez-Rodríguez

Esther Nérida Sánchez-Rodríguez

Auto-generated profile, based on publicly available information

Esther Nérida Sánchez-Rodríguez

Programa de Doctorado en Farmacologia, Departamento de Fisiología, Instituto de Terapéutica Experimental y Clínica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2019 in International Journal of Food Sciences and Nutrition
Verified
Journal Article
Closed access
PQPatricia Quezada-Fernández
Patricia Quezada-Fernández
JTJhonatan Trujillo-Quiros
Jhonatan Trujillo-Quiros
SPSara Pascoe-González
Sara Pascoe-González
WTWalter A. Trujillo-Rangel
Walter A. Trujillo-Rangel
DCDavid Cardona-Müller
David Cardona-Müller
FGFernando Grover-Páez
Fernando Grover-Páez
Type 2 diabetes mellitus (T2DM) is associated with premature atherosclerosis and arterial stiffening due to the accumulation of advanced glycation end-products in vessel walls. Green tea polyphenols are considered cardio-protective substances. In this randomised double-blind placebo-controlled trial (NCT02627898), we evaluated the effect of Green tea extract on arterial stiffness parameters, lipids, body composition and sRAGE levels. Twenty normotensive patients with T2DM treated with the standard therapy and statins, mean age 53.2 ± 9.4 years and mean BMI 30.1 ± 4.5 kg/m2, were randomised to receive a daily dose of 400 mg of green tea extract (polyphenols ≥90%, EGCG ≥45%) or placebo for 12 weeks. Compared to placebo, administration of green tea extract decreased central augmentation index (-3.05 ± 10.8% vs. 6.7 ± 0.1%, p = .04). These findings suggest that green tea extract could be used as an adjunct to the standard therapy to improve arterial stiffness in T2DM.

16 April 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MVMaria Luisa Vazquez-Villegas
Maria Luisa Vazquez-Villegas
JGJorge I. Gamez-Nava
Jorge I. Gamez-Nava
ASA. Miriam Saldaña-Cruz
A. Miriam Saldaña-Cruz
ARALFREDO DE JESUS CELIS-DE LA ROSA
ALFREDO DE JESUS CELIS-DE LA ROSA
ESEsther N. Sanchez-Rodriguez
Esther N. Sanchez-Rodriguez
LLLaura Gonzalez Lopez
Laura Gonzalez Lopez
Adipokines, especially chemerin, can interact with cytokines and other molecules in inflammation. To date, there is insufficient information regarding a possible correlation between functional disability and chemerin and other pro-inflammatory molecules in rheumatoid arthritis (RA). To identify the association of functional disability with serum chemerin and other pro-inflammatory molecules, including other adipokines, cytokines and E-selectin, in patients with RA. Cross-sectional study. Assessment: disease activity (DAS28-ESR) and functional disability (HAQ-DI). We compared the adipokines (chemerin, leptin, adiponectin, resistin, and visfatin), cytokines (TNF-α, IL-6, IL-1β, and IL-18) and E-selectin levels between RA with functional disability and RA non-disabled patients. Of 82 patients with RA, 43 (52%) had functional disability. The RA with functional disability group had higher chemerin (140 vs. 112 ng/mL, p = 0.007) than the non-disabled RA group. Chemerin correlated with the HAQ-DI (rho = 0.27, p = 0.02) and DAS28-ESR (rho = 0.21, p = 0.05). Severe activity correlated with IL-6 (rho = 0.33, p = 0.003) and E-selectin (rho = 0.23, p = 0.03) but not with disability. No other pro-inflammatory molecules correlated with HAQ-DI. High chemerin levels were associated with functional disability in RA, whereas no other molecules correlated with loss of function. These results encourage further studies assessing new roles of chemerin as a marker of impairment in RA.